{"id":129,"date":"2020-10-02T11:26:59","date_gmt":"2020-10-02T10:26:59","guid":{"rendered":"http:\/?page_id=129"},"modified":"2024-06-27T08:30:52","modified_gmt":"2024-06-27T07:30:52","slug":"alain-gardier","status":"publish","type":"page","link":"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/?page_id=129","title":{"rendered":"Alain Gardier"},"content":{"rendered":"\n<figure class=\"wp-block-image is-style-rounded\"><img loading=\"lazy\" decoding=\"async\" width=\"220\" height=\"220\" src=\"http:\/wp-content\/uploads\/2020\/09\/2020_AMG_NB.png\" alt=\"\" class=\"wp-image-104\" srcset=\"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/wp-content\/uploads\/2020\/09\/2020_AMG_NB.png 220w, http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/wp-content\/uploads\/2020\/09\/2020_AMG_NB-150x150.png 150w\" sizes=\"(max-width: 220px) 100vw, 220px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">PROFESSOR<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">PharmD, PhD<\/h3>\n\n\n\n<p><a href=\"Tel: &nbsp;+33(0)1.80.00.63.37\">Tel: &nbsp;+33(0)1.80.00.63.37<\/a><\/p>\n\n\n\n<ul class=\"wp-block-social-links is-layout-flex wp-block-social-links-is-layout-flex\">\n\n\n\n<li class=\"wp-social-link wp-social-link-mail  wp-block-social-link\"><a href=\"mailto:alain.gardier@universite-paris-saclay.fr\" class=\"wp-block-social-link-anchor\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" version=\"1.1\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" aria-hidden=\"true\" focusable=\"false\"><path d=\"M19,5H5c-1.1,0-2,.9-2,2v10c0,1.1.9,2,2,2h14c1.1,0,2-.9,2-2V7c0-1.1-.9-2-2-2zm.5,12c0,.3-.2.5-.5.5H5c-.3,0-.5-.2-.5-.5V9.8l7.5,5.6,7.5-5.6V17zm0-9.1L12,13.6,4.5,7.9V7c0-.3.2-.5.5-.5h14c.3,0,.5.2.5.5v.9z\"><\/path><\/svg><span class=\"wp-block-social-link-label screen-reader-text\">Mail<\/span><\/a><\/li>\n\n<li class=\"wp-social-link wp-social-link-twitter  wp-block-social-link\"><a href=\"https:\/\/twitter.com\/alain_gardier\" class=\"wp-block-social-link-anchor\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" version=\"1.1\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" aria-hidden=\"true\" focusable=\"false\"><path d=\"M22.23,5.924c-0.736,0.326-1.527,0.547-2.357,0.646c0.847-0.508,1.498-1.312,1.804-2.27 c-0.793,0.47-1.671,0.812-2.606,0.996C18.324,4.498,17.257,4,16.077,4c-2.266,0-4.103,1.837-4.103,4.103 c0,0.322,0.036,0.635,0.106,0.935C8.67,8.867,5.647,7.234,3.623,4.751C3.27,5.357,3.067,6.062,3.067,6.814 c0,1.424,0.724,2.679,1.825,3.415c-0.673-0.021-1.305-0.206-1.859-0.513c0,0.017,0,0.034,0,0.052c0,1.988,1.414,3.647,3.292,4.023 c-0.344,0.094-0.707,0.144-1.081,0.144c-0.264,0-0.521-0.026-0.772-0.074c0.522,1.63,2.038,2.816,3.833,2.85 c-1.404,1.1-3.174,1.756-5.096,1.756c-0.331,0-0.658-0.019-0.979-0.057c1.816,1.164,3.973,1.843,6.29,1.843 c7.547,0,11.675-6.252,11.675-11.675c0-0.178-0.004-0.355-0.012-0.531C20.985,7.47,21.68,6.747,22.23,5.924z\"><\/path><\/svg><span class=\"wp-block-social-link-label screen-reader-text\">Twitter<\/span><\/a><\/li>\n\n\n\n\n\n\n\n<\/ul>\n\n\n\n<pre class=\"wp-block-preformatted\"><a rel=\"noreferrer noopener\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=gardier%2Bam&amp;sort=date\" target=\"_blank\"><h3 class=\"wp-svg-library library\"><\/h3><\/a>\n<\/pre>\n\n\n\n<h3 class=\"wp-block-heading\">Area of Research<\/h3>\n\n\n\n<p>Neuropharmacology, Neurobiology of anxiety\/depression, Neurochemistry, Animal Models of Psychiatric Disorders.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Expertise<\/h3>\n\n\n\n<p>Links between neurotropins and serotonergic systems<\/p>\n\n\n\n<p>Intracerebral Microdialysis, HPLC<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Research Theme<\/h3>\n\n\n\n<p>After pharmacy studies, followed by an internship (Paris Hospitals), a PhD Thesis in Neuropharmacology led me to study the serotoninergic mechanisms of drugs (anti-obesity, antidepressants) related to the BDNF, a neurotrophic factor. During my post-doctoral fellowship at MIT (USA), I acquired innovative microsurgery and neurochemistry techniques (e.g., intracerebral microdialysis, knockout mice, animal models of anxiety-depression), and I established solid collaborations maintained by multiple stays. As a teacher-researcher, I led a small team (EA3544), before co-directing with Pr E. Corruble, psychiatrist, a \u00ab\u00a0mixed\u00a0\u00bb medicine \/ pharmacy team (Inserm, University Paris-Sud \/ Paris-Saclay) on the topic of antidepressant drug resistance. In this exhilarating activity, I federate a teaching and a dynamic and competitive research team with&nbsp; Colleagues mastering complementary approaches, within which we share a same vision of the fascinating profession of academic. Thus, we have recently shown that the fast antidepressant effect of ketamine, an NMDA glutamate receptor antagonist, is driven by a glutamate (excitation) \/ GABA (inhibition) balance acceleration in a neuronal circuit involving the prefrontal medial cortex. This opens new therapeutic avenues in a field, depression, lacking recent innovations.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Selected Publications<\/h3>\n\n\n\n<p>\u00a0<\/p>\n\n\n\n<p>Nguyen, T. M. L., F. Jollant, L. Tritschler, R. Colle, E. Corruble and A. M. Gardier (2024). \u00ab\u00a0[Ketamine and suicidal behavior: Contribution of animal models of aggression-impulsivity to understanding its mechanism of action].\u00a0\u00bb Ann Pharm Fr 82(1): 3-14.<br><\/p>\n\n\n\n<p>Nguyen, T. M. L., J.-P. Guilloux, C. Defaix, I. Mendez-David, I. Etting, J.-C. Alvarez, J. C. McGowan, J. N. Highland, P. Zanos, J. Lovett, R. Moaddel, E. Corruble, D. J. David, T. D. Gould, C. A. Denny and A. M. Gardier (2024). \u00ab\u00a0Ketamine metabolism via hepatic CYP450 isoforms contributes to its sustained antidepressant actions.\u00a0\u00bb bioRxiv.<\/p>\n\n\n\n<p>Nguyen, T. M. L., F. Jollant, L. Tritschler, R. Colle, E. Corruble and A. M. Gardier (2023). \u00ab\u00a0Pharmacological Mechanism of Ketamine in Suicidal Behavior Based on Animal Models of Aggressiveness and Impulsivity: A Narrative Review.\u00a0\u00bb Pharmaceuticals (Basel) 16(4).<br><\/p>\n\n\n\n<p>Nguyen, T. M. L., C. Defaix, I. Mendez-David, L. Tritschler, I. Etting, J. C. Alvarez, W. Choucha, R. Colle, E. Corruble, D. J. David and A. M. Gardier (2023). \u00ab\u00a0Intranasal (R, S)-ketamine delivery induces sustained antidepressant effects associated with changes in cortical balance of excitatory\/inhibitory synaptic activity.\u00a0\u00bb Neuropharmacology 225: 109357.<br><\/p>\n\n\n\n<p>Jollant, F., R. Colle, T. M. L. Nguyen, E. Corruble, A. M. Gardier, M. Walter, M. Abbar and G. Wagner (2023). \u00ab\u00a0Ketamine and esketamine in suicidal thoughts and behaviors: a systematic review.\u00a0\u00bb Ther Adv Psychopharmacol 13: 20451253231151327.<br><\/p>\n\n\n\n<p>Guilloux, J. P., T. M. L. Nguyen and A. M. Gardier (2023). \u00ab\u00a0[Ketamine: a neuropsychotropic drug with an innovative mechanism of action].\u00a0\u00bb Biol Aujourdhui 217(3-4): 133-144.<br><\/p>\n\n\n\n<p>Doan, J., C. Defaix, I. Mendez-David, A. M. Gardier, R. Colle, E. Corruble, J. C. McGowan, D. J. David, J. P. Guilloux and L. Tritschler (2023). \u00ab\u00a0Intrahippocampal injection of a selective blocker of NMDA receptors containing the GluN2B subunit, Ro25-6981, increases glutamate neurotransmission and induces antidepressant-like effects.\u00a0\u00bb Fundam Clin Pharmacol.<br><\/p>\n\n\n\n<p>Chen, B. K., V. M. Luna, M. Jin, A. Shah, M. E. Shannon, M. Pauers, B. L. Williams, V. Pham, H. C. Hunsberger, A. M. Gardier, I. Mendez-David, D. J. David and C. A. Denny (2023). \u00ab\u00a0A tale of two receptors: simultaneous targeting of NMDARs and 5-HT (4) Rs exerts additive effects against stress.\u00a0\u00bb bioRxiv.<br><\/p>\n\n\n\n<p>Nguyen, T. M. L., J. C. McGowan and A. M. Gardier (2022). \u00ab\u00a0CYP 450 enzymes influence (R,S)-ketamine brain delivery and its antidepressant activity.\u00a0\u00bb Neuropharmacology 206: 108936.<br><\/p>\n\n\n\n<p>Mendez-David, I., R. Schofield, L. Tritschler, R. Colle, J. P. Guilloux, A. M. Gardier, E. Corruble, R. Hen and D. J. David (2022). \u00ab\u00a0Reviving through human hippocampal newborn neurons.\u00a0\u00bb Encephale 48(2): 179-187.<br><\/p>\n\n\n\n<p>Lebeau, R. H., I. Mendez-David, L. Kucynski-Noyau, C. Henry, D. Attali, M. Plaze, R. Colle, E. Corruble, A. M. Gardier, R. Gaillard, J. P. Guilloux and D. J. David (2022). \u00ab\u00a0Peripheral proteomic changes after electroconvulsive seizures in a rodent model of non-response to chronic fluoxetine.\u00a0\u00bb Front Pharmacol 13: 993449.<br><\/p>\n\n\n\n<p>Dallerac, G., X. Li, P. Lecouflet, N. Morisot, S. Sacchi, R. Asselot, T. H. Pham, B. Potier, D. J. G. Watson, S. Schmidt, G. Levasseur, P. Fossat, A. Besedin, J. M. Rivet, J. T. Coyle, G. Collo, L. Pollegioni, J. Kehr, M. Galante, K. C. Fone, A. M. Gardier, T. Freret, A. Contarino, M. J. Millan and J. P. Mothet (2021). \u00ab\u00a0Dopaminergic neuromodulation of prefrontal cortex activity requires the NMDA receptor coagonist d-serine.\u00a0\u00bb Proc Natl Acad Sci U S A 118(23).<br><\/p>\n\n\n\n<p>Pham, T. H., C. Defaix, T. M. L. Nguyen, I. Mendez-David, L. Tritschler, D. J. David and A. M. Gardier (2020). \u00ab\u00a0Cortical and raphe GABAA, AMPA receptors and glial GLT-1 glutamate transporter contribute to the sustained antidepressant activity of ketamine.\u00a0\u00bb Pharmacol Biochem Behav 192: 172913.<br><\/p>\n\n\n\n<p>Faye, C., R. Hen, B. P. Guiard, C. A. Denny, A. M. Gardier, I. Mendez-David and D. J. David (2020). \u00ab\u00a0Rapid Anxiolytic Effects of RS67333, a Serotonin Type 4 Receptor Agonist, and Diazepam, a Benzodiazepine, Are Mediated by Projections From the Prefrontal Cortex to the Dorsal Raphe Nucleus.\u00a0\u00bb Biol Psychiatry 87(6): 514-525.<br><\/p>\n\n\n\n<p>Colle, R., K. El Asmar, C. Verstuyft, P. M. Lledo, F. Lazarini, K. Chappell, E. Deflesselle, A. E. K. Ait Tayeb, B. Falissard, E. Duron, S. Rotenberg, J. F. Costemale-Lacoste, D. J. David, F. Gressier, A. M. Gardier, T. Hummel, L. Becquemont and E. Corruble (2020). \u00ab\u00a0The olfactory deficits of depressed patients are restored after remission with venlafaxine treatment.\u00a0\u00bb Psychol Med: 1-9.<br><\/p>\n\n\n\n<p>Chen, B. K., I. Mendez-David, V. M. Luna, C. Faye, A. M. Gardier, D. J. David and C. A. Denny (2020). \u00ab\u00a0Prophylactic efficacy of 5-HT4R agonists against stress.\u00a0\u00bb Neuropsychopharmacology 45(3): 542-552.<br><\/p>\n\n\n\n<p>Chen, B. K., V. M. Luna, C. T. LaGamma, X. Xu, S. X. Deng, R. F. Suckow, T. B. Cooper, A. Shah, R. A. Brachman, I. Mendez-David, D. J. David, A. M. Gardier, D. W. Landry and C. A. Denny (2020). \u00ab\u00a0Sex-specific neurobiological actions of prophylactic (R,S)-ketamine, (2R,6R)-hydroxynorketamine, and (2S,6S)-hydroxynorketamine.\u00a0\u00bb Neuropsychopharmacology 45(9): 1545-1556.<br><\/p>\n\n\n\n<p>Tutakhail, A., Q. A. Nazari, S. Khabil, A. Gardier and F. Coudore (2019). \u00ab\u00a0Muscular and mitochondrial effects of long-term fluoxetine treatment in mice, combined with physical endurance exercise on treadmill.\u00a0\u00bb Life Sci 232: 116508.<br><\/p>\n\n\n\n<p>Pham, T. H. and A. M. Gardier (2019). \u00ab\u00a0Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies.\u00a0\u00bb Pharmacol Ther 199: 58-90.<\/p>\n\n\n\n<p>Mendez-David, I., D. J. David, C. Delomenie, L. Tritchler, J. M. Beaulieu, R. Colle, E. Corruble, A. M. Gardier and R. Hen (2023). \u00ab\u00a0A complex relation between levels of adult hippocampal neurogenesis and expression of the immature neuron marker doublecortin.\u00a0\u00bb Hippocampus.<\/p>\n\n\n\n<p>Chen, B. K., I. Mendez-David, V. M. Luna, C. Faye, A. M. Gardier, D. J. David and C. A. Denny (2019). \u00ab\u00a0Prophylactic efficacy of 5-HT4R agonists against stress.\u00a0\u00bb Neuropsychopharmacology.<\/p>\n\n\n\n<p>&nbsp;Tutakhail, A., Q. A. Nazari, S. Khabil, A. Gardier and F. Coudore (2019). \u00ab\u00a0Muscular and mitochondrial effects of long-term fluoxetine treatment in mice, combined with physical endurance exercise on treadmill.\u00a0\u00bb Life Sci 232: 116508.<\/p>\n\n\n\n<p>&nbsp;Faye, C., R. Hen, B. P. Guiard, C. A. Denny, A. M. Gardier, I. Mendez-David and D. J. David (2019). \u00ab\u00a0Rapid anxiolytic effects of RS67333, a serotonin type 4 receptor agonist, and diazepam, a benzodiazepine, are mediated by projections from the prefrontal cortex to the dorsal raphe nucleus.\u00a0\u00bb Biol Psychiatry. In Press<\/p>\n\n\n\n<p>&nbsp;Doan, J., A. M. Gardier and L. Tritschler (2019). \u00ab\u00a0Role of adult-born granule cells in the hippocampal functions: Focus on the GluN2B-containing NMDA receptors.\u00a0\u00bb Eur Neuropsychopharmacol. In press.<\/p>\n\n\n\n<p>&nbsp;Pham, T. H. and A. M. Gardier (2019). \u00ab\u00a0Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies.\u00a0\u00bb Pharmacol Ther. In press.<\/p>\n\n\n\n<p>&nbsp;Felice, D., J. P. Guilloux, A. Pehrson, Y. Li, I. Mendez-David, A. M. Gardier, C. Sanchez and D. J. David (2018). \u00ab\u00a0Vortioxetine Improves Context Discrimination in Mice Through a Neurogenesis Independent Mechanism.\u00a0\u00bb Front Pharmacol 9: 204.&nbsp;<\/p>\n\n\n\n<p>&nbsp;Defaix C., A. Solgadi, T. H. Pham, A. M. Gardier, P. Chaminade, L. Tritschler (2018).&nbsp;Rapid analysis of glutamate, glutamine and GABA in mice frontal cortex microdialysis samples using HPLC coupled to electrospray tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis.<\/p>\n\n\n\n<p>&nbsp;Tritschler, L., M. A. Kheirbek, Y. L. Dantec, I. Mendez-David, J. P. Guilloux, C. Faye, J. Doan, T. H. Pham, R. Hen, D. J. David and A. M. Gardier (2017). \u00ab\u00a0Optogenetic activation of granule cells in the dorsal dentate gyrus enhances dopaminergic neurotransmission in the Nucleus Accumbens.\u00a0\u00bb Neurosci Res.<\/p>\n\n\n\n<p>&nbsp;Pham, T. H., C. Defaix, X. Xu, S. X. Deng, N. Fabresse, J. C. Alvarez, D. W. Landry, R. A. Brachman, C. A. Denny and A. M. Gardier (2017). \u00ab\u00a0Common Neurotransmission Recruited in (R,S)-Ketamine and (2R,6R)-Hydroxynorketamine-Induced Sustained Antidepressant-like Effects.\u00a0\u00bb Biol Psychiatry.<\/p>\n\n\n\n<p>&nbsp;Petit, A. C., K. El Asmar, D. J. David, A. M. Gardier, L. Becquemont, B. Feve, C. Verstuyft and E. Corruble (2018). \u00ab\u00a0The association of beta-arrestin2 polymorphisms with response to antidepressant treatment in depressed patients.\u00a0\u00bb Prog Neuropsychopharmacol Biol Psychiatry 81: 74-79.<\/p>\n\n\n\n<p>&nbsp;Mendez-David, I., C. Boursier, V. Domergue, R. Colle, B. Falissard, E. Corruble, A. M. Gardier, J. P. Guilloux and D. J. David (2017). \u00ab\u00a0Differential Peripheral Proteomic Biosignature of Fluoxetine Response in a Mouse Model of Anxiety\/Depression.\u00a0\u00bb Front Cell Neurosci 11: 237.&nbsp;<\/p>\n\n\n\n<p>&nbsp;Mendez-David, I., J. P. Guilloux, M. Papp, L. Tritschler, E. Mocaer, A. M. Gardier, S. Bretin and D. J. David (2017). \u00ab\u00a0S 47445 Produces Antidepressant- and Anxiolytic-Like Effects through Neurogenesis Dependent and Independent Mechanisms.\u00a0\u00bb Front Pharmacol 8: 462.<\/p>\n\n\n\n<p>&nbsp;Guilloux, J. P., A. M. Gardier and D. J. David (2017). \u00ab\u00a0New targets and modalities of antidepressant drugs development.\u00a0\u00bb La lettre du Pharmacologue 31(1): 12-18.<\/p>\n\n\n\n<p>&nbsp;Lugert, S., T. Kremer, R. Jagasia, A. Herrmann, S. Aigner, C. Giachino, I. Mendez-David, A. M. Gardier, J. P. Carralot, H. Meistermann, A. Augustin, M. D. Saxe, J. Lamerz, G. Duran-Pacheco, A. Ducret, V. Taylor, D. J. David and C. Czech (2017). \u00ab\u00a0Glypican-2 levels in cerebrospinal fluid predict the status of adult hippocampal neurogenesis.\u00a0\u00bb Sci Rep 7: 46543.<\/p>\n\n\n\n<p>&nbsp;Garcia-Garcia, A. L., Q. Meng, S. Canetta, A. M. Gardier, B. P. Guiard, C. Kellendonk, A. Dranovsky and E. D. Leonardo (2017). \u00ab\u00a0Serotonin Signaling through Prefrontal Cortex 5-HT1A Receptors during Adolescence Can Determine Baseline Mood-Related Behaviors.\u00a0\u00bb Cell Rep 18(5): 1144-1156.<\/p>\n\n\n\n<p>&nbsp;Mekiri, M., A. M. Gardier, D. J. David and J. P. Guilloux (2017). \u00ab\u00a0Chronic corticosterone administration effects on behavioral emotionality in female c57bl6 mice.\u00a0\u00bb Exp Clin Psychopharmacol 25(2): 94-104.<\/p>\n\n\n\n<p>&nbsp;Guilloux, J. P., B. A. Samuels, I. Mendez-David, A. Hu, M. Levinstein, C. Faye, M. Mekiri, E. Mocaer, A. M. Gardier, R. Hen, A. Sors and D. J. David (2017). \u00ab\u00a0S 38093, a histamine H3 antagonist\/inverse agonist, promotes hippocampal neurogenesis and improves context discrimination task in aged mice.\u00a0\u00bb Sci Rep 7: 42946.<\/p>\n\n\n\n<p>&nbsp;Pham, T. H., I. Mendez-David, C. Defaix, B. P. Guiard, L. Tritschler, D. J. David and A. M. Gardier (2017). \u00ab\u00a0Ketamine treatment involves medial prefrontal cortex serotonin to induce a rapid antidepressant-like activity in BALB\/cJ mice.\u00a0\u00bb Neuropharmacology 112(Pt A): 198-209.<\/p>\n\n\n\n<p>&nbsp;Nautiyal, K. M., L. Tritschler, S. E. Ahmari, D. J. David, A. M. Gardier and R. Hen (2016). \u00ab\u00a0A Lack of Serotonin 1B Autoreceptors Results in Decreased Anxiety and Depression-Related Behaviors.\u00a0\u00bb Neuropsychopharmacology 41(12): 2941-2950.<\/p>\n\n\n\n<p>&nbsp;Besson, M., S. Guiducci, S. Granon, J. P. Guilloux, B. Guiard, C. Reperant, P. Faure, S. Pons, G. Cannazza, M. Zoli, A. M. Gardier and U. Maskos (2016). \u00ab\u00a0Alterations in alpha5* nicotinic acetylcholine receptors result in midbrain- and hippocampus-dependent behavioural and neural impairments.\u00a0\u00bb Psychopharmacology (Berl) 233(18): 3297-3314.<\/p>\n\n\n\n<p>&nbsp;David, D. J. and A. M. Gardier (2016). \u00ab\u00a0[The pharmacological basis of the serotonin system: Application to antidepressant response].\u00a0\u00bb Encephale 42(3): 255-263.<\/p>\n\n\n\n<p>&nbsp;David D. J., L. Tritschler, J. P. Guilloux, A. M. Gardier, C. Sanchez, R. Gaillard (2016). \u00ab\u00a0Pharmacological properties of vortioxetine and its pre-clinical consequences.\u00a0\u00bb Enc\u00e9phale. 42: 1S12<\/p>\n\n\n\n<p>&nbsp;Darcet, F., A. M. Gardier, R. Gaillard, D. J. David and J. P. Guilloux (2016). \u00ab\u00a0Cognitive Dysfunction in Major Depressive Disorder. A Translational Review in Animal Models of the Disease.\u00a0\u00bb Pharmaceuticals (Basel) 9(1).<\/p>\n\n\n\n<p>&nbsp;Darcet, F., A. M. Gardier, D. J. David and J. P. Guilloux (2016). \u00ab\u00a0Chronic 5-HT receptor agonist treatment restores learning and memory deficits in a neuroendocrine mouse model of anxiety\/depression.\u00a0\u00bb Neurosci Lett 616: 197-203.<\/p>\n\n\n\n<p>&nbsp;Quesseveur, G., A. C. Petit, H. T. Nguyen, L. Dahan, R. Colle, S. Rotenberg, I. Seif, P. Robert, D. David, J. P. Guilloux, A. M. Gardier, C. Verstuyft, L. Becquemont, E. Corruble and B. P. Guiard (2016). \u00ab\u00a0Genetic dysfunction of serotonin 2A receptor hampers response to antidepressant drugs: A translational approach.\u00a0\u00bb Neuropharmacology 105: 142-153.<\/p>\n\n\n\n<p>&nbsp;Samuels, B. A., I. Mendez-David, C. Faye, S. A. David, K. A. Pierz, A. M. Gardier, R. Hen and D. J. David (2016). \u00ab\u00a0Serotonin 1A and Serotonin 4 Receptors: Essential Mediators of the Neurogenic and Behavioral Actions of Antidepressants.\u00a0\u00bb Neuroscientist 22(1): 26-45.<\/p>\n\n\n\n<p>&nbsp;Schloesser, R. J., S. Orvoen, D. V. Jimenez, N. F. Hardy, K. R. Maynard, M. Sukumar, H. K. Manji, A. M. Gardier, D. J. David and K. Martinowich (2015). \u00ab\u00a0Antidepressant-like Effects of Electroconvulsive Seizures Require Adult Neurogenesis in a Neuroendocrine Model of Depression.\u00a0\u00bb Brain Stimul 8(5): 862-867.<\/p>\n\n\n\n<p>&nbsp;Felice, D., O. F. O&rsquo;Leary, J. F. Cryan, T. G. Dinan, A. M. Gardier, C. Sanchez and D. J. David (2015). \u00ab\u00a0When ageing meets the blues: Are current antidepressants effective in depressed aged patients?\u00a0\u00bb Neurosci Biobehav Rev 55: 478-497<\/p>\n\n\n\n<p>&nbsp;Brachman, R. A., J. C. MCGowan, J. N. Perusini, S. C. Lim, T. H. Pham, C. Faye, A. M. Gardier, I. Mendez-David, D. J. David, R. Hen and C. A. Denny (2015). \u00ab\u00a0Ketamine as a prophylactic against stress-induced depressive-like behavior.\u00a0\u00bb Biological Psychiatry In Press.<\/p>\n\n\n\n<p>&nbsp;Nautiyal, K. M., K. F. Tanaka, M. M. Barr, L. Tritschler, Y. Le Dantec, D. J. David, A. M. Gardier, C. Blanco, R. Hen and S. E. Ahmari (2015). \u00ab\u00a0Distinct Circuits Underlie the Effects of 5-HT1B Receptors on Aggression and Impulsivity.\u00a0\u00bb Neuron 86(3): 813-826.<\/p>\n\n\n\n<p>&nbsp;Mendez-David, I., L. Tritschler, Z. E. Ali, M. H. Damiens, M. Pallardy, D. J. David, S. Kerdine-Romer and A. M. Gardier (2015). \u00ab\u00a0Nrf2-signaling and BDNF: A new target for the antidepressant-like activity of chronic fluoxetine treatment in a mouse model of anxiety\/depression.\u00a0\u00bb Neurosci Lett 597: 121-126.<\/p>\n\n\n\n<p>&nbsp;Tritschler, L., D. Felice, R. Colle, J. P. Guilloux, E. Corruble, A. M. Gardier and D. J. David (2014). \u00ab\u00a0Vortioxetine for the treatment of major depressive disorder.\u00a0\u00bb Expert Rev Clin Pharmacol: 1-15.<\/p>\n\n\n\n<p>&nbsp;Courouss\u00e9, T., A. Bacq, C. Belzung, B. Guiard, L. Balasse, F. Louis, A. M. Le Guisquet, A. M. Gardier, A. H. Schinkel, B. Giros and S. Gautron (2014). \u00ab\u00a0Brain organic cation transporter 2 controls response and vulnerability to stress and GSK3beta signaling.\u00a0\u00bb Mol Psychiatry 20(7): 889-900.<\/p>\n\n\n\n<p>&nbsp;Hache, G., B. P. Guiard, T. H. Nguyen, G. Quesseveur, A. M. Gardier, D. Peters, G. Munro and F. Coudore (2015). \u00ab\u00a0Antinociceptive activity of the new triple reuptake inhibitor NS18283 in a mouse model of chemotherapy-induced neuropathic pain.\u00a0\u00bb Eur J Pain 19(3): 322-333.<\/p>\n\n\n\n<p>&nbsp;Darcet, F., I. Mendez-David, L. Tritschler, A. M. Gardier, J. P. Guilloux and D. J. David (2014). \u00ab\u00a0Learning and memory impairments in a neuroendocrine mouse model of anxiety\/depression.\u00a0\u00bb Front Behav Neurosci 8: 136.<\/p>\n\n\n\n<p>&nbsp;Petit, A. C., G. Quesseveur, F. Gressier, R. Colle, D. J. David, A. M. Gardier, F. Ferreri, J. P. Lepine, B. Falissard, C. Verstuyft, B. P. Guiard and E. Corruble (2014). \u00ab\u00a0Converging translational evidence for the involvement of the serotonin 2A receptor gene in major depressive disorder.\u00a0\u00bb Prog Neuropsychopharmacol Biol Psychiatry 54: 76-82.<\/p>\n\n\n\n<p>&nbsp;Mendez-David, I., D. J. David, F. Darcet, M. V. Wu, S. Kerdine-Romer, A. M. Gardier and R. Hen (2014). \u00ab\u00a0Rapid Anxiolytic Effects of a 5-HT Receptor Agonist Are Mediated by a Neurogenesis-Independent Mechanism.\u00a0\u00bb Neuropsychopharmacology. In Press<\/p>\n\n\n\n<p>&nbsp;Mendez-David, I., Z. El-Ali, R. Hen, B. Falissard, E. Corruble, A. M. Gardier, S. Kerdine-Romer and D. J. David (2013). \u00ab\u00a0A method for biomarker measurements in peripheral blood mononuclear cells isolated from anxious and depressed mice: beta-arrestin 1 protein levels in depression and treatment.\u00a0\u00bb Front Pharmacol 4: 124.<\/p>\n\n\n\n<p>&nbsp;Quesseveur, G., A. M. Gardier and B. P. Guiard (2013). \u00ab\u00a0The monoaminergic tripartite synapse: a putative target for currently available antidepressant drugs.\u00a0\u00bb Curr Drug Targets 14(11): 1277-1294.<\/p>\n\n\n\n<p>&nbsp;Gardier, A. M. (2013). \u00ab\u00a0Antidepressant activity: contribution of brain microdialysis in knock-out mice to the understanding of BDNF\/5-HT transporter\/5-HT autoreceptor interactions.\u00a0\u00bb Front Pharmacol 4: 98.<\/p>\n\n\n\n<p>&nbsp;Pla, P., S. Orvoen, C. Benstaali, S. Dodier, A. M. Gardier, D. J. David, S. Humbert and F. Saudou (2013). \u00ab\u00a0Huntingtin acts non cell-autonomously on hippocampal neurogenesis and controls anxiety-related behaviors in adult mouse.\u00a0\u00bb PLoS One 8(9): e73902.<\/p>\n\n\n\n<p>&nbsp;Guilloux, J. P., I. Mendez-David, A. Pehrson, B. P. Guiard, C. Reperant, S. Orvoen, A. M. Gardier, R. Hen, B. Ebert, S. Miller, C. Sanchez and D. J. David (2013). \u00ab\u00a0Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice.\u00a0\u00bb Neuropharmacology 73: 147-159.<\/p>\n\n\n\n<p>&nbsp;Nguyen, H. T., B. P. Guiard, A. Bacq, D. J. David, I. David, G. Quesseveur, S. Gautron, C. Sanchez and A. M. Gardier (2013). \u00ab\u00a0Blockade of the high-affinity noradrenaline transporter (NET) by the selective 5-HT reuptake inhibitor escitalopram: an in vivo microdialysis study in mice.\u00a0\u00bb Br J Pharmacol 168(1): 103-116.<\/p>\n\n\n\n<p>&nbsp;Quesseveur, G., C. Reperant, D. J. David, A. M. Gardier, C. Sanchez and B. P. Guiard (2013). \u00ab\u00a05-HT(2)A receptor inactivation potentiates the acute antidepressant-like activity of escitalopram: involvement of the noradrenergic system.\u00a0\u00bb Exp Brain Res 226(2): 285-295.<\/p>\n\n\n\n<p>&nbsp;Quesseveur, G., D. J. David, M. C. Gaillard, P. Pla, M. V. Wu, H. T. Nguyen, V. Nicolas, G. Auregan, I. David, A. Dranovsky, P. Hantraye, R. Hen, A. M. Gardier, N. Deglon and B. P. Guiard (2013). \u00ab\u00a0BDNF overexpression in mouse hippocampal astrocytes promotes local neurogenesis and elicits anxiolytic-like activities.\u00a0\u00bb Transl Psychiatry 3: e253.<\/p>\n\n\n\n<p>&nbsp;Mendez-David, I., R. Hen, A. M. Gardier and D. J. David (2013). \u00ab\u00a0Adult hippocampal neurogenesis: an actor in the antidepressant-like action.\u00a0\u00bb Ann Pharm Fr 71(3): 143-149.<\/p>\n\n\n\n<p>&nbsp;Ben M&rsquo;Barek, K., P. Pla, S. Orvoen, C. Benstaali, J. D. Godin, A. M. Gardier, F. Saudou, D. J. David and S. Humbert (2013). \u00ab\u00a0Huntingtin mediates anxiety\/depression-related behaviors and hippocampal neurogenesis.\u00a0\u00bb J Neurosci 33(20): 8608-8620.<\/p>\n\n\n\n<p>&nbsp;Tolu, S., R. Eddine, F. Marti, V. David, M. Graupner, S. Pons, M. Baudonnat, M. Husson, M. Besson, C. Reperant, J. Zemdegs, C. Pages, Y. A. Hay, B. Lambolez, J. Caboche, B. Gutkin, A. M. Gardier, J. P. Changeux, P. Faure and U. Maskos (2013). \u00ab\u00a0Co-activation of VTA DA and GABA neurons mediates nicotine reinforcement.\u00a0\u00bb Mol Psychiatry 18(3): 382-393.&nbsp;<\/p>\n\n\n\n<p>&nbsp;Quesseveur, G., H. T. Nguyen, A. M. Gardier and B. P. Guiard (2012). \u00ab\u00a05-HT2 ligands in the treatment of anxiety and depression.\u00a0\u00bb Expert opinion on investigational drugs 21(11): 1701-1725.<\/p>\n\n\n\n<p>&nbsp;Xia, L., C. Delomenie, I. David, Q. Rainer, M. Marouard, H. Delacroix, D. J. David, A. M. Gardier and J. P. Guilloux (2012). \u00ab\u00a0Ventral hippocampal molecular pathways and impaired neurogenesis associated with 5-HT(1)A and 5-HT(1)B receptors disruption in mice.\u00a0\u00bb Neuroscience letters 521(1): 20-25.<\/p>\n\n\n\n<p>&nbsp;Hache, G., B. P. Guiard, Y. Le Dantec, S. Orvoen, D. J. David, A. M. Gardier and F. Coudore (2012). \u00ab\u00a0Antinociceptive effects of fluoxetine in a mouse model of anxiety\/depression.\u00a0\u00bb Neuroreport 23(9): 525-529.<\/p>\n\n\n\n<p>&nbsp;Nguyen, H. T., B. P. Guiard, A. Bacq, D. J. David, I. David, G. Quesseveur, S. Gautron, C. Sanchez and A. M. Gardier (2012). \u00ab\u00a0Blockade of the high-affinity norepinephrine transporter (NET) by the selective serotonin reuptake inhibitor escitalopram: an in vivo microdialysis study in mice.\u00a0\u00bb British journal of pharmacology.(In press)<\/p>\n\n\n\n<p>&nbsp;Rainer, Q., H. T. Nguyen, G. Quesseveur, A. M. Gardier, D. J. David and B. P. Guiard (2012). \u00ab\u00a0Functional status of somatodendritic serotonin 1A autoreceptor after long-term treatment with fluoxetine in a mouse model of anxiety\/depression based on repeated corticosterone administration.\u00a0\u00bb Molecular pharmacology 81(2): 106-112.<\/p>\n\n\n\n<p>&nbsp;Orvoen, S., P. Pla, A. M. Gardier, F. Saudou and D. J. David (2012). \u00ab\u00a0Huntington&rsquo;s disease knock-in male mice show specific anxiety-like behaviour and altered neuronal maturation.\u00a0\u00bb Neuroscience letters 507(2): 127-132.<\/p>\n\n\n\n<p>&nbsp;Besson, M., V. David, M. Baudonnat, P. Cazala, J. P. Guilloux, C. Reperant, I. Cloez-Tayarani, J. P. Changeux, A. M. Gardier and S. Granon (2012). \u00ab\u00a0Alpha7-nicotinic receptors modulate nicotine-induced reinforcement and extracellular dopamine outflow in the mesolimbic system in mice.\u00a0\u00bb Psychopharmacology 220(1): 1-14.<\/p>\n\n\n\n<p>&nbsp;Guilloux, J. P., G. Douillard-Guilloux, R. Kota, X. Wang,&nbsp;A. M. Gardier, K. Martinowich, G. C. Tseng, D. A. Lewis and E. Sibille (2012). \u00ab\u00a0Molecular evidence for BDNF- and GABA-related dysfunctions in the amygdala of female subjects with major depression.\u00a0\u00bb Molecular psychiatry 17(11): 1130-1142.<\/p>\n\n\n\n<p>&nbsp;Samuels, B. A., E. D. Leonardo, R. Gadient, A. Williams, J. Zhou, D. J. David, A. M. Gardier, E. H. Wong and R. Hen (2011). \u00ab\u00a0Modeling treatment-resistant depression.\u00a0\u00bb Neuropharmacology 61(3): 408-413.<\/p>\n\n\n\n<p>&nbsp;Guilloux, J. P., D. J. David, L. Xia, H. T. Nguyen, Q. Rainer, B. P. Guiard, C. Reperant, T. Deltheil, M. Toth, R. Hen and A. M. Gardier (2011). \u00ab\u00a0Characterization of 5-HT(1A\/1B)-\/- mice: an animal model sensitive to anxiolytic treatments.\u00a0\u00bb Neuropharmacology 61(3): 478-488.<\/p>\n\n\n\n<p>&nbsp;Richardson-Jones, J. W., C. P. Craige, T. H. Nguyen, H. F. Kung, A. M. Gardier, A. Dranovsky, D. J. David, B. P. Guiard, S. G. Beck, R. Hen and E. D. Leonardo (2011). \u00ab\u00a0Serotonin-1A Autoreceptors Are Necessary and Sufficient for the Normal Formation of Circuits Underlying Innate Anxiety.\u00a0\u00bb J Neurosci 31(16): 6008-6018.<\/p>\n\n\n\n<p>&nbsp;Rainer, Q., L. Xia, J. P. Guilloux, C. Gabriel, E. Mocaer, R. Hen, E. Enhamre, A. M. Gardier and D. J. David (2011). \u00ab\u00a0Beneficial behavioural and neurogenic effects of agomelatine in a model of depression\/anxiety.\u00a0\u00bb Int J Neuropsychopharmacol: 1-15.<\/p>\n\n\n\n<p>&nbsp;Hache, G., F. Coudore, A. M. Gardier and B. Guiard (2011). \u00ab\u00a0Monoaminergic Antidepressants in the Relief of Pain: Potential Therapeutic Utility of Triple Reuptake Inhibitors (TRIs).\u00a0\u00bb Pharmaceuticals 4(2): 285-342.<\/p>\n\n\n\n<p>&nbsp;David, D. J., J. Wang, B. A. Samuels, Q. Rainer, I. David, A. M. Gardier and R. Hen (2010). \u00ab\u00a0Implications of the functional integration of adult-born hippocampal neurons in anxiety-depression disorders.\u00a0\u00bb Neuroscientist 16(5): 578-591.<\/p>\n\n\n\n<p>&nbsp;Richardson-Jones, J.W., Caryne P. Craige, Bruno P. Guiard, Alisson Stephen, Kayla L. Metzger, Hank F. Kung, Alain M. Gardier, Alex Dranovsky, Denis J. David, Sheryl G. Beck, Ren\u00e9 Hen, E. David Leonardo (2010). \u00a0\u00bb 5-HT1A Autoreceptor Levels Determine Vulnerability to Stress and Response to Antidepressants.\u00a0\u00bbNeuron 65(1): 40-52.<\/p>\n\n\n\n<p>&nbsp;Amilhon, B., E. Lepicard, T. Renoir, R. Mongeau, D. Popa, O. Poirel, S. Miot, C. Gras, A. M. Gardier, J. Gallego, M. Hamon, L. Lanfumey, B. Gasnier, B. Giros and S. El Mestikawy (2010). \u00ab\u00a0VGLUT3 (vesicular glutamate transporter type 3) contribution to the regulation of serotonergic transmission and anxiety.\u00a0\u00bb J Neurosci 30(6): 2198-2210.<\/p>\n\n\n\n<p>&nbsp;Popa, D., J. Cerdan, C. Reperant, B. P. Guiard, J. P. Guilloux, D. J. David and A. M. Gardier (2010). \u00ab\u00a0A longitudinal study of 5-HT outflow during chronic fluoxetine treatment using a new technique of chronic microdialysis in a highly emotional mouse strain.\u00a0\u00bb Eur J Pharmacol 628(1-3): 83-90.<\/p>\n\n\n\n<p>&nbsp;Reperant, C., S. Pons, E. Dufour, H. Rollema, A. M. Gardier and U. Maskos (2010). \u00ab\u00a0Effect of the alpha4beta2* nicotinic acetylcholine receptor partial agonist varenicline on dopamine release in beta2 knock-out mice with selective re-expression of the beta2 subunit in the ventral tegmental area.\u00a0\u00bb Neuropharmacology 58(2): 346-350.<\/p>\n\n\n\n<p>&nbsp;Rainer, Q., A. M. Gardier, R. Hen and D. J. David (2009). \u00ab\u00a0Neurogenesis-dependent and independent effects of anti-depressant drugs.\u00a0\u00bb Med Sci (Paris) 25(10): 795-798.<\/p>\n\n\n\n<p>&nbsp;David, D. J., B. A. Samuels, Q. Rainer, J. W. Wang, D. Marsteller, I. Mendez, M. Drew, D. A. Craig, B. P. Guiard, J. P. Guilloux, R. P. Artymyshyn, A. M. Gardier, C. Gerald, I. A. Antonijevic, E. D. Leonardo and R. Hen (2009). \u00ab\u00a0Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety\/depression.\u00a0\u00bb Neuron 62(4): 479-493.<\/p>\n\n\n\n<p>&nbsp;Commentaires in Lledo P.M.(2009). \u00ab\u00a0Dissecting the pathophysiology of depression with a Swiss army knife.\u00a0\u00bb Neuron 62(4): 453-455.&nbsp;<\/p>\n\n\n\n<p>&nbsp;Gardier, A. M., B. P. Guiard, J. P. Guilloux, C. Reperant, F. Coudore and D. J. David (2009). \u00ab\u00a0Interest of using genetically manipulated mice as models of depression to evaluate antidepressant drugs activity: a review.\u00a0\u00bb Fundam Clin Pharmacol 23(1): 23-42.<\/p>\n\n\n\n<p>&nbsp;Gardier, A. M., B. P. Guiard, J. P. Guilloux, C. Reperant, F. Coudore and D. J. David (2009). \u00ab\u00a0Interest of using genetically manipulated mice as models of depression to evaluate antidepressant drugs activity: a review.\u00a0\u00bb Fundam Clin Pharmacol 23(1): 23-42.<\/p>\n\n\n\n<p>&nbsp;Gardier, A. M. (2009). \u00ab\u00a0Mutant mouse models and antidepressant drug research: focus on serotonin and brain-derived neurotrophic factor.\u00a0\u00bb Behav Pharmacol 20(1): 18-32.<\/p>\n\n\n\n<p>&nbsp;Deltheil, T., K. Tanaka, C. Reperant, R. Hen, D. J. David and A. M. Gardier (2009). \u00ab\u00a0Synergistic neurochemical and behavioural effects of acute intrahippocampal injection of brain-derived neurotrophic factor and antidepressants in adult mice.\u00a0\u00bb Int J Neuropsychopharmacol: 1-11.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Book Chapters<\/h3>\n\n\n\n<p>&nbsp;Mendez-David, I., D. J. David, J.-P. Guilloux, R. Hen and A. M. Gardier (2015). \u00ab\u00a05-HT4 Receptor Subtype, \u03b2-Arrestin Level, and Rapid-Onset Effects of Antidepressant Drugs.\u00a0\u00bb&nbsp; 95: 101-121.<\/p>\n\n\n\n<p>&nbsp;Samuels, B., I. David, D. J. David, A. M. Gardier and R. Hen (2014). Role of hippocampal neurogenesis in the mechanism of action of antidepressant\/anxiolytic drugs in animal model of depression and anxiety. Neurobiology of mood disorders. B. P. Guiard and E. Dremencov, Bentham Science Publishers: 210-233.<\/p>\n\n\n\n<p>&nbsp;Gardier, A. M. (2014). Intracerebral in vivo microdialysis in knockout mice : advantages and drawbacks. Neurobiology of mood disorders. B. P. Guiard and E. Dremencov, Bentham Science Publishers: 3-22.<\/p>\n\n\n\n<p>&nbsp;David, D. J., B. P. Guiard, J. P. Guilloux and A. M. Gardier (2013). Pharmacologie des antid\u00e9presseurs : mod\u00e8les animaux. Les Antid\u00e9presseurs. E. Corruble. Paris, Flammarion M\u00e9decine\/Sciences: 40-51.<\/p>\n\n\n\n<p>&nbsp;Guilloux, J. P., D. J. David, B. A. Samuels, I. David, A. M. Gardier and B. P. Guiard (2012). Non-response to initial antidepressant therapy. Psychology. Rijeka, Croatia, InTech.<\/p>\n\n\n\n<p>&nbsp;Deltheil, T., B. Guiard, J. P. Guilloux, D. David, F. Coudore and A. M. Gardier (2012). S\u00e9rotonine et facteurs neurotrophiques dans la d\u00e9pression. S\u00e9rotonine: aspects biologiques et cliniques. O. Spreux-Varoquaux. Paris, Lavoisier &#8211; M\u00e9decine Sciences. 1: 329-370.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>PROFESSOR PharmD, PhD Tel: &nbsp;+33(0)1.80.00.63.37 Area of Research Neuropharmacology, Neurobiology of anxiety\/depression, Neurochemistry, Animal Models of Psychiatric Disorders. Expertise Links between neurotropins and serotonergic systems Intracerebral Microdialysis, HPLC Research Theme After pharmacy studies, followed by an internship (Paris Hospitals), a PhD Thesis in Neuropharmacology led me to study the serotoninergic mechanisms of drugs (anti-obesity, antidepressants)&hellip; <br \/> <a class=\"read-more\" href=\"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/?page_id=129\">Lire la suite<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"_links":{"self":[{"href":"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/index.php?rest_route=\/wp\/v2\/pages\/129"}],"collection":[{"href":"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=129"}],"version-history":[{"count":24,"href":"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/index.php?rest_route=\/wp\/v2\/pages\/129\/revisions"}],"predecessor-version":[{"id":615,"href":"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/index.php?rest_route=\/wp\/v2\/pages\/129\/revisions\/615"}],"wp:attachment":[{"href":"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=129"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}